These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25695772)

  • 1. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
    Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
    PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.
    Bearss DJ; Subler MA; Hundley JE; Troyer DA; Salinas RA; Windle JJ
    Oncogene; 2000 Feb; 19(8):1114-22. PubMed ID: 10713698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
    Brodie SG; Xu X; Li C; Kuo A; Leder P; Deng CX
    Oncogene; 2001 Mar; 20(12):1445-54. PubMed ID: 11313888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
    Weyandt J
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
    Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
    Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
    Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE
    Mol Cell Biol; 1998 Jan; 18(1):85-92. PubMed ID: 9418856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.
    Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR
    J Clin Invest; 2007 Jul; 117(7):1893-901. PubMed ID: 17607363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.
    Petit T; Bearss DJ; Troyer DA; Munoz RM; Windle JJ
    Mol Cancer Ther; 2003 Feb; 2(2):165-71. PubMed ID: 12589033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53.
    Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Subler MA; Windle JJ
    Mol Cell Biol; 1997 Feb; 17(2):723-31. PubMed ID: 9001226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
    Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
    Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.
    Zhang Z; Yao R; Li J; Wang Y; Boone CW; Lubet RA; You M
    Mol Cancer Res; 2005 Oct; 3(10):563-74. PubMed ID: 16254190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
    Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
    Adhikari AS; Iwakuma T
    Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
    McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
    Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.